Research Monitoring
What changed
in the evidence.
Evidence is not static, and neither are our grades. This is the public log of what moved — new trials, regulatory actions, and every time we changed a compound's grade, with the source that prompted it.
Recent trial changes
Detected between ClinicalTrials.gov syncs · 2026-10-11A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Added to Synptide tracking
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Added to Synptide tracking
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Added to Synptide tracking
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Added to Synptide tracking
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Added to Synptide tracking
A Retrospective Real-World Cohort Study
Added to Synptide tracking
Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study
Added to Synptide tracking
Probiotics in Obese Patients Treated With Semaglutide
Added to Synptide tracking
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
Added to Synptide tracking
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
Added to Synptide tracking
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
Added to Synptide tracking
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Added to Synptide tracking
Recent trial activity
Auto-updated from ClinicalTrials.gov · synced 2026-10-11Tirzepatide for the Treatment of Cannabis Use Disorder
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Evidence-grade change log
July 2026
Synptide launches the compound directory and evidence-grading system
We published canonical, outcome-graded profiles for the first 25 compounds, plus a public A–U evidence framework and this change log.
Semaglutide graded A for cardiovascular risk reduction on SELECT evidence
We set semaglutide's cardiovascular-outcome grade to A after the SELECT trial's 20% reduction in major cardiovascular events.